Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Non-Current Liabilities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $693.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 11.75% to $693.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $693.3 million, a 11.75% increase, with the full-year FY2025 number at $693.3 million, up 11.75% from a year prior.
  • Total Non-Current Liabilities was $693.3 million for Q4 2025 at Phathom Pharmaceuticals, up from $651.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $693.3 million in Q4 2025 to a low of $103.5 million in Q1 2022.
  • A 4-year average of $424.5 million and a median of $486.1 million in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 127.86% in 2024, then increased 11.75% in 2025.
  • Phathom Pharmaceuticals' Total Non-Current Liabilities stood at $232.1 million in 2022, then soared by 105.45% to $476.9 million in 2023, then skyrocketed by 30.09% to $620.4 million in 2024, then increased by 11.75% to $693.3 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Total Non-Current Liabilities are $693.3 million (Q4 2025), $651.3 million (Q3 2025), and $644.6 million (Q2 2025).